CN111386107A - 丙磺舒在治疗癫痫性疾病、病症或病况中的用途 - Google Patents

丙磺舒在治疗癫痫性疾病、病症或病况中的用途 Download PDF

Info

Publication number
CN111386107A
CN111386107A CN201880059798.3A CN201880059798A CN111386107A CN 111386107 A CN111386107 A CN 111386107A CN 201880059798 A CN201880059798 A CN 201880059798A CN 111386107 A CN111386107 A CN 111386107A
Authority
CN
China
Prior art keywords
probenecid
acid
pharmaceutically acceptable
epilepsy
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880059798.3A
Other languages
English (en)
Chinese (zh)
Inventor
N·鲁阿什
E·多西
G·于贝菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Science Technology And Literature In Paris Latin District
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Universite Paris Cite
Original Assignee
Science Technology And Literature In Paris Latin District
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Universite de Paris
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Science Technology And Literature In Paris Latin District, Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Universite de Paris, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Science Technology And Literature In Paris Latin District
Priority to CN202510416283.6A priority Critical patent/CN120478323A/zh
Publication of CN111386107A publication Critical patent/CN111386107A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201880059798.3A 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途 Pending CN111386107A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510416283.6A CN120478323A (zh) 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305934.6A EP3427729A1 (en) 2017-07-13 2017-07-13 Probenecid for use in treating epileptic diseases, disorders or conditions
EP17305934.6 2017-07-13
PCT/EP2018/069092 WO2019012109A1 (en) 2017-07-13 2018-07-13 PROBENECID FOR USE IN THE TREATMENT OF EPILEPTIC DISEASES, DISORDERS OR DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510416283.6A Division CN120478323A (zh) 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途

Publications (1)

Publication Number Publication Date
CN111386107A true CN111386107A (zh) 2020-07-07

Family

ID=59384111

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510416283.6A Pending CN120478323A (zh) 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途
CN201880059798.3A Pending CN111386107A (zh) 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202510416283.6A Pending CN120478323A (zh) 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途

Country Status (6)

Country Link
US (2) US12318358B2 (enExample)
EP (2) EP3427729A1 (enExample)
JP (1) JP7369693B2 (enExample)
CN (2) CN120478323A (enExample)
CA (1) CA3070178A1 (enExample)
WO (1) WO2019012109A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230134678A1 (en) * 2021-11-02 2023-05-04 Kaohsiung Chang Gung Memorial Hospital Ketogenic dietary evaluation system and operation method thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011238A (es) 2020-03-11 2022-10-07 Iterum Therapeutics International Ltd Combinaciones de compuestos beta-lactamicos, probenecid y acido valproico y sus usos.
EP4505999A1 (en) 2023-08-07 2025-02-12 Panntherapi Probenecid formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0501378A1 (en) * 1991-02-28 1992-09-02 Merrell Dow Pharmaceuticals Inc. NMDA Antagonists
US5407935A (en) * 1991-09-09 1995-04-18 Warner-Lambert Company Pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US902695A (en) 1907-12-31 1908-11-03 Stasia B Staley Package-tie.
JPS586027A (ja) 1981-07-01 1983-01-13 住友電気工業株式会社 高圧ケ−ブルの接続部
GB2104078B (en) 1981-08-14 1985-01-23 London Polytech New aminoacid isomers, their production and their medicinal use
NL8500847A (nl) 1984-03-29 1985-10-16 Sandoz Ag Gesubstitueerde alfa-aminozuren, hun bereiding en farmaceutische preparaten die ze bevatten.
CA1248531A (en) 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
US4906621A (en) 1985-05-24 1990-03-06 Ciba-Geigy Corporation Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade
US4746653A (en) 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US4657899A (en) 1986-04-09 1987-04-14 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors
US4812458A (en) 1986-09-16 1989-03-14 A/S Ferrosan 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
IE66149B1 (en) 1986-09-16 1995-12-13 Novo Nordisk As Quinoxaline compounds and their preparation and use
US4705781A (en) 1986-10-08 1987-11-10 Giba-Geigy Corporation Method of treating cerebral ischemia using 4-(phosphono substituted lower alkyl or lower alkenyl)piperazine-2-carboxylic acids and salts, esters and amides thereof
GB8625941D0 (en) 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
IL84492A0 (en) 1986-11-21 1988-04-29 Ciba Geigy Ag Unsaturated phosphonic acids and derivatives
GB8703749D0 (en) 1987-02-18 1987-03-25 Sandoz Ltd Piperazinecarboxylic acid
US4761405A (en) 1987-03-04 1988-08-02 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency
DK146787A (da) 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
EP0302826A3 (de) 1987-08-04 1991-04-03 Ciba-Geigy Ag Verfahren zur Herstellung neuer ungesättigter Aminosäureverbindungen
GB8719102D0 (en) 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
US4918064A (en) 1987-10-21 1990-04-17 G. D. Searle & Co. Phenyl glycines for use in reducing neurotoxic injury
NO179551C (no) 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
GB8727792D0 (en) 1987-11-27 1987-12-31 Merck Sharp & Dohme Therapeutic agents
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US4968678A (en) 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
JPH0210544A (ja) 1988-06-29 1990-01-16 Canon Inc 光磁気記憶装置
DE68912822T2 (de) 1988-05-16 1994-06-09 Searle & Co 2-Amino-4,5-methylenadipinsäure-Verbindungen für die Behandlung von CNS-Erkrankungen.
DK160941C (da) 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
GB8823605D0 (en) 1988-10-07 1988-11-16 Merck Sharp & Dohme Therapeutic agents
CA2000901A1 (en) 1988-10-21 1990-04-21 Alexis A. Cordi Phosphono-hydroisoquinoline compounds useful in reducing neurotoxic injury
DK716188D0 (da) 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DK715888D0 (da) 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
US5187171A (en) 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
ATE147732T1 (de) 1989-03-08 1997-02-15 Merck Sharp & Dohme Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US4902687A (en) 1989-03-27 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
DE59007300D1 (de) 1989-04-07 1994-11-03 Ciba Geigy Ag Ungesättigte Aminodicarbonsäurederivate.
GB8908529D0 (en) 1989-04-14 1989-06-01 Merck Sharp & Dohme Therapeutic agents
US4960786A (en) 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
JPH0347123A (ja) 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
AU632362B2 (en) 1989-09-19 1992-12-24 Merrell Dow Pharmaceuticals Inc. Nmda antagonists
DE59009368D1 (de) 1989-09-26 1995-08-10 Ciba Geigy Ag Phosphonsäure, Verfahren zur Herstellung und Verwendung als Arzneimittelwirkstoff.
US5318985A (en) 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0501378A1 (en) * 1991-02-28 1992-09-02 Merrell Dow Pharmaceuticals Inc. NMDA Antagonists
US5407935A (en) * 1991-09-09 1995-04-18 Warner-Lambert Company Pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALAN C FOSTER ET AL: "Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid", 《NEUROSCIENCE LETTERS》 *
ALAN C FOSTER ET AL: "Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid", 《NEUROSCIENCE LETTERS》, vol. 48, 31 December 1984 (1984-12-31), pages 273 - 278 *
ANA LAURA COLIN-GONZALEZ: "Probenecid: An emerging tool for neuroprotection", 《CNS & NEUROLOGICAL DISORDERS》 *
ANA LAURA COLIN-GONZALEZ: "Probenecid: An emerging tool for neuroprotection", 《CNS & NEUROLOGICAL DISORDERS》, vol. 12, no. 7, 31 December 2013 (2013-12-31), pages 1050 - 1065, XP009501812, DOI: 10.2174/18715273113129990090 *
LASZLO VECSEI ET AL.,: "Kynurenine and Probenecid Inhibit Pentylenetetrazol- and NMDLA-Induced Seizures and Increase Kynurenic Acid Concentrations in the Brain", 《BRAIN RESEATCH BULLETIN》, vol. 28, pages 233 - 238 *
龚云: "丙磺舒逆转多药耐药相关蛋白的表达在难治性癫痫治疗中的作用", 《中风与神经疾病杂志》 *
龚云: "丙磺舒逆转多药耐药相关蛋白的表达在难治性癫痫治疗中的作用", 《中风与神经疾病杂志》, vol. 22, no. 6, 31 December 2005 (2005-12-31), pages 569 - 571 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230134678A1 (en) * 2021-11-02 2023-05-04 Kaohsiung Chang Gung Memorial Hospital Ketogenic dietary evaluation system and operation method thereof
US12484834B2 (en) * 2021-11-02 2025-12-02 Kaohsiung Chang Gung Memorial Hospital Ketogenic dietary evaluation system and operation method thereof

Also Published As

Publication number Publication date
US20250288544A1 (en) 2025-09-18
US12318358B2 (en) 2025-06-03
US20200163916A1 (en) 2020-05-28
JP2020527172A (ja) 2020-09-03
WO2019012109A1 (en) 2019-01-17
RU2020106762A (ru) 2021-08-13
EP3651758A1 (en) 2020-05-20
JP7369693B2 (ja) 2023-10-26
CA3070178A1 (en) 2019-01-17
EP3427729A1 (en) 2019-01-16
RU2020106762A3 (enExample) 2021-11-10
CN120478323A (zh) 2025-08-15

Similar Documents

Publication Publication Date Title
US20250288544A1 (en) Probenecid for use in treating epileptic diseases, disorders or conditions
KR102547164B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
JP2024516421A (ja) Ｍｄｍａ鏡像異性体
US20220133652A1 (en) A formulation for improving seizure control
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
US20250032503A1 (en) Use of aprepitant for treating alzheimer's disease
CN1794992A (zh) 治疗轻度认知缺损及预防或延缓阿尔茨海默病的方法
CN113329749B (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
JP2024519866A (ja) 神経学的疾患を治療するための方法及び組成物
US20230355618A1 (en) Raf inhibitor for treating low grade glioma
JP7697110B2 (ja) 精神神経障害を処置するための組成物および方法
RU2785842C2 (ru) Применение пробенецида для лечения эпилептических заболеваний, нарушений и состояний
EP3096790B1 (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CN113242735A (zh) 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
US20080051403A1 (en) Treatment For Alzheimer's Disease And Related Conditions
US20060183764A1 (en) Combination of gh secret agogues and pde4 inhibitors for the treatment of alzheimers disease
JPWO2021156769A5 (enExample)
JP5714572B2 (ja) 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法
US20150031765A1 (en) Treatment of cognitive impairment
US20140045863A1 (en) Muscarinic Agonists as Cognitive Enhancers
JPWO2000007593A1 (ja) 難治性てんかんの治療薬又は予防薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Paris France

Applicant after: Science, technology and literature in Paris - Latin District

Applicant after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant after: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Applicant after: SORBONNE UNIVERSITE

Applicant after: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Applicant after: COMMISSARIAT a L'eNERGIE ATOMIQUE ET AUX eNERGIES ALTERNATIVES

Applicant after: University of Western dais, Paris

Address before: Paris France

Applicant before: Science, technology and literature in Paris - Latin District

Applicant before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant before: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Applicant before: SORBONNE UNIVERSITE

Applicant before: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Applicant before: COMMISSARIAT a L'eNERGIE ATOMIQUE ET AUX eNERGIES ALTERNATIVES

Applicant before: University of Paris

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Paris France

Applicant after: Paris foundation for science and Literature

Applicant after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant after: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Applicant after: SORBONNE UNIVERSITE

Applicant after: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Applicant after: COMMISSARIAT a L'eNERGIE ATOMIQUE ET AUX eNERGIES ALTERNATIVES

Applicant after: University of Western dais, Paris

Address before: Paris France

Applicant before: Science, technology and literature in Paris - Latin District

Applicant before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Applicant before: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Applicant before: SORBONNE UNIVERSITE

Applicant before: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Applicant before: COMMISSARIAT a L'eNERGIE ATOMIQUE ET AUX eNERGIES ALTERNATIVES

Applicant before: University of Western dais, Paris

CB02 Change of applicant information